Conference Coverage
Early MS biomarkers may improve prediction of long-term outcomes
Combining two biomarkers may shed more light on MS prognosis.
Combining two biomarkers may shed more light on MS prognosis.
B-cell depletion following ocrelizumab or rituximab treatment often lasts longer than 6 months.
A randomized trial demonstrates how to deliver therapy at home.
The likelihood of achieving pregnancy through assisted reproductive technologies while having MS appeared favorable.
A new prospective trial aims to prove that central vein sign can distinguish MS from clinical mimics.
Open-label study confirms efficacy and COVID-19–related safety.
A prospective study found improved neutralizing antibody response with more time elapsed since therapy and vaccination.
The presence and number of iron rim lesions hold a prognostic value for long-term disability in MS.
This is a potentially important biomarker for disease progression that may otherwise go unrecognized by clinicians and patients.